Semaglutide weight loss results: what the data says vs. TikTok

What's this video probably claiming?

Based on the caption, Chelsea is documenting a 43-pound weight loss, dropping from 163 lbs to 120 lbs, attributed to semaglutide obtained through ShedRx, a telehealth prescribing platform. That's a roughly 26% reduction in body weight. Videos in this genre typically walk through before-and-after photos, describe the injection routine, discuss side effects like nausea or appetite suppression, and position the drug as straightforwardly transformative. They often imply the results are typical, replicable, and primarily drug-driven, with little attention to dosing timelines, dietary changes, or medical supervision. Given ShedRx is tagged directly, there's also an implicit endorsement angle here, whether paid or organic. The framing almost certainly centers on dramatic visual change as the primary evidence of the drug's efficacy.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) remains the landmark reference. In 1,961 adults with obesity but without diabetes, 2.4 mg subcutaneous semaglutide weekly for 68 weeks produced a mean body weight reduction of 14.9%, compared to 2.4% with placebo. Roughly one-third of participants lost 20% or more of body weight. A 26% loss like Chelsea describes falls at the higher end of the distribution, not the average. The STEP 4 trial (Rubino et al., 2021, JAMA) also showed that stopping semaglutide after 20 weeks led to substantial weight regain within a year, averaging two-thirds of lost weight. So the drug works, genuinely, but the magnitude varies widely and durability depends heavily on continued use. Most clinical results are achieved over 12 to 18 months, not weeks.

Where does the social media noise diverge from clinical reality?

Several gaps exist between this type of content and clinical reality. First, individual results like a 43-pound loss make compelling content but are not representative of the median outcome. Second, TikTok weight loss videos rarely disclose the full behavioral context: caloric intake changes, exercise, baseline metabolic health, or whether the person also had a caloric deficit independent of drug effects. Third, ShedRx and similar telehealth platforms prescribe compounded semaglutide in many cases, which is chemically distinct in formulation from FDA-approved Wegovy. Compounded versions have not undergone the same efficacy and safety trials. The FDA has explicitly warned that compounded semaglutide products are not FDA-approved and carry unknown risk profiles (FDA Drug Safety Communication, 2024). Conflating results from brand-name trials with compounded product use is a serious accuracy problem in this content category.

What should you actually know?

Semaglutide is a legitimate, well-studied medication with real clinical evidence behind it. A 26% weight reduction is possible but sits at the optimistic end of trial data. What these videos almost never address is the rebound risk. The STEP 4 data is sobering: most people regain significant weight within 12 months of stopping. There's also a side effect profile worth understanding. In STEP 1, over 70% of semaglutide users reported gastrointestinal side effects, with nausea affecting 44% and vomiting affecting 24%. Rare but serious risks include pancreatitis and, in rodent studies, thyroid C-cell tumors, though human relevance remains under study. Weight loss journeys documented on TikTok, especially with brand tagging, should be read as anecdote, not evidence. If you're considering semaglutide, that conversation belongs with a licensed provider who reviews your full medical history, not an influencer's before-and-after reel.